Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,475 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Feasibility of Nitroglycerin Patch as a Pretreatment for the Distal Radial Approach: Study Protocol for a Randomized Controlled Trial (DRANG Study).
Murai K, Fujino M, Ito S, Imazu M, Arai M, Iwai T, Sawada K, Matama H, Miura H, Honda S, Yoneda S, Takagi K, Otsuka F, Kataoka Y, Asaumi Y, Tahara Y, Tsujita K, Noguchi T. Murai K, et al. Among authors: ito s. Cardiovasc Revasc Med. 2022 Oct;43:43-48. doi: 10.1016/j.carrev.2022.05.010. Epub 2022 May 13. Cardiovasc Revasc Med. 2022. PMID: 35597718
An Exploratory Study of Dapagliflozin for the Attenuation of Albuminuria in Patients with Heart Failure and Type 2 Diabetes Mellitus (DAPPER).
Yoshihara F, Imazu M, Hamasaki T, Anzai T, Yasuda S, Ito S, Yamamoto H, Hashimura K, Yasumura Y, Mori K, Watanabe M, Asakura M, Kitakaze M; DAPPER investigators and study coordinators. Yoshihara F, et al. Among authors: ito s. Cardiovasc Drugs Ther. 2018 Apr;32(2):183-190. doi: 10.1007/s10557-018-6782-1. Cardiovasc Drugs Ther. 2018. PMID: 29589153
Effects of Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes Mellitus in Open-Label, Marker-Stratified Randomized, Parallel-Group Comparison, Standard Treatment-Controlled Multicenter Trial (TOPLEVEL Study): Rationale and Study Design.
Imazu M, Nakano A, Ito S, Hamasaki T, Kitakaze M; TOPLEVEL investigators and study coordinators. Imazu M, et al. Among authors: ito s. Cardiovasc Drugs Ther. 2019 Jun;33(3):363-370. doi: 10.1007/s10557-019-06871-3. Cardiovasc Drugs Ther. 2019. PMID: 30850916
Rationale and Design of a Prospective, Multicenter, Single-Arm Clinical Trial to Investigate the Safety and Effectiveness of Rotablator Atherectomy System as an Adjunctive Device for Endovascular Treatment of Occlusive Atherosclerotic Lesions in Below-the-Knee Arteries With Critical Limb Ischemia (RESCUE-BTK).
Yagyu T, Ito S, Kawarada O, Mizuseki M, Yamamoto H, Asakura M, Funabashi S, Onda K, Ohshima K, Fukuda-Doi M, Asakura K, Kitakaze M, Noguchi T, Yasuda S. Yagyu T, et al. Among authors: ito s. Circ Rep. 2020 Jun 16;2(8):449-454. doi: 10.1253/circrep.CR-20-0024. Circ Rep. 2020. PMID: 33693268 Free PMC article.
DAPagliflozin for the attenuation of albuminuria in Patients with hEaRt failure and type 2 diabetes (DAPPER study): a multicentre, randomised, open-label, parallel-group, standard treatment-controlled trial.
Yoshihara F, Imazu M, Sakuma I, Hiroi Y, Hara H, Okazaki O, Ishiguro C, Izumi C, Noguchi T, Shiraiwa T, Nishioka N, Fujii K, Iwakura K, Tomonaga O, Kobayashi K, Takihata M, Yumoto K, Takase H, Himi T, Shimizu I, Murakami T, Wagatsuma K, Sato K, Hiramatsu T, Akabame S, Hata S, Asakura M, Kawabata T, Omae K, Ito S, Kitakaze M; DAPPER Investigators. Yoshihara F, et al. Among authors: ito s. EClinicalMedicine. 2023 Nov 27;66:102334. doi: 10.1016/j.eclinm.2023.102334. eCollection 2023 Dec. EClinicalMedicine. 2023. PMID: 38192595 Free PMC article.
9,475 results